Skip to main content

Advertisement

SpringerLink
Log in

Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis

  • Letter to the Editor
  • Published:
Rheumatology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829

    Article  PubMed  CAS  Google Scholar 

  2. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162–1167

    Article  PubMed  CAS  Google Scholar 

  3. Iwamoto M, Homma S, Asano Y, Minota S (2005) Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand J Rheumatol 34:410–411

    Article  PubMed  CAS  Google Scholar 

  4. Singh R, Cuchacovich R, Huang W, Espinoza LR (2002) Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Reumatol 29:636–637

    Google Scholar 

  5. Sugioka Y, Inui K, Koike T (2008) Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Mod Rheumatol 18:293–295

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

M. Iwamoto and S. Minota are inventors in the patent of tocilizumab applicable to systemic or polyarthritic juvenile idiopathic arthritis, and the measurement of serum concentration of tocilizumab was supported by Chugai pharmaceutical Co., Ltd.

Author information

Authors and Affiliations

  1. Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, 329-0498, Japan

    Masahiro Iwamoto & Seiji Minota

  2. Koga Red Cross Hospital, Ibaraki, Japan

    Sumiko Honma & Yasushi Asano

Authors
  1. Masahiro Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumiko Honma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasushi Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seiji Minota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masahiro Iwamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iwamoto, M., Honma, S., Asano, Y. et al. Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis. Rheumatol Int 31, 559–560 (2011). https://doi.org/10.1007/s00296-010-1430-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1430-5

Keywords

Search

Navigation